Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC
| Autor: | Yuichiro Ohe, Tatsuya Yoshida, Noboru Yamamoto, Takashi Kubo, Noriko Motoi, Yuji Matsumoto, Kouya Shiraishi, Yuki Shinno, Hidehito Horinouchi, Masayuki Shirasawa, Yasushi Goto, Koichi Goto, Sachiyo Mitani, Daisuke Takayanagi, Takashi Kohno, Yusuke Okuma, Hitoshi Ichikawa, Shingo Matsumoto, Shun-ichi Watanabe, Ken Masuda, Yukiko Shimoda |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
Oncology medicine.medical_specialty Programmed cell death Lung Neoplasms Lymphocyte Clone (cell biology) CD8-Positive T-Lymphocytes B7-H1 Antigen Lymphocytes Tumor-Infiltrating Immune system Carcinoma Non-Small-Cell Lung Internal medicine Tumor Microenvironment medicine Humans Immune Checkpoint Inhibitors Retrospective Studies Tumor microenvironment Predictive marker business.industry Blockade medicine.anatomical_structure Immunohistochemistry Apoptosis Regulatory Proteins business |
| Zdroj: | Journal of Thoracic Oncology. 16:2078-2090 |
| ISSN: | 1556-0864 |
| DOI: | 10.1016/j.jtho.2021.07.027 |
| Popis: | Introduction Programmed death-ligand 1 (PD-L1) expression is not a completely reliable predictive marker of the efficacy of anti–programmed cell death protein-1 (PD-1)/PD-L1 therapy in patients with advanced NSCLC. Immune-related tumor microenvironment (TME) is classified into four different types based on the tumor-infiltrating lymphocyte (TIL) status and PD-L1 expression. Methods We retrospectively reviewed patients with advanced NSCLC treated with anti–PD-1/PD-L1 therapy between 2015 and 2019. We investigated the association between the efficacy of anti–PD-1/PD-L1 therapy, the types of TME based on PD-L1 (clone: 22C3) expression, the density of CD8-positive TILs assessed by immunohistochemistry, and mutational profiles by next-generation sequencing. Results Overall, 228 patients were included in the analysis. The patients were classified into the following four groups: type I: PD-L1High (tumor proportion score ≥ 50%)/TILHigh (≥85/mm2; n = 73); type II: PD-L1Low (tumor proportion score Conclusions Differential types of TME, including PD-L1 expression and TIL status, could accurately predict the efficacy of anti–PD-1/PD-L1 therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|